Q3 2024
Released Feb 12, 2024, before the open
10-Q filed Feb 12, 2024, 43 days after period end · 0001764013-24-000026
Q3 2024 · 10-Q
Revenue—
Net Income-$51.42M-$51.42M N/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$0.36-$0.36 N/M vs Q3 2023N/M vs Q2 2024
Operating Cash Flowderived-$47,098,000N/M
Free Cash Flowderived-$47,229,000N/M
What the release said
The release
Same quarter
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2018 |
|---|---|---|---|---|
| Net Income | -$51.42M | -$63.23M | -$41.39M | -$8.85M |
| EPS Diluted | -$0.36 | -$0.49 | -$0.36 | -$0.24 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR